A Newcastle biotech business developing nanorobots to help diagnose deadly diseases at an early stage is set to ramp up plans for commercialisation on the back of a successful NHS trial and £1.85m investment.
Nanovery was launched in 2018 by Dr Jurek Kozyra, who wanted to create a more efficient diagnostics solution for serious diseases, with the goal to bring more regular testing to clinicians and patients. Now a trial to test the accuracy of the Nanovery technology compared to traditional methods has been hailed for having the potential to transform the time and costs associated with diagnosing serious cancers.
Based at the Biospehere at Newcastle Helix, the firm is developing nanorobots for a quick and easy test to help diagnose cancer and other diseases. The test is based on DNA nanotechnology and the company says it costs less than tissue biopsy, while reducing risk to patients. The company was originally established in London, but made the move to Tyneside in 2020, where it could collaborate with Newcastle’s academics and partners in the field of research and development, including Newcastle University and Newcastle Centre for Cancer.
